Business Context and Reporting Period
Company: Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Ginkgo operates two segments: Cell Engineering (biological R&D services, automation tools, and data generation) and Biosecurity (biomonitoring and bioinformatics services). The company is executing a restructuring plan initiated in 2024 to reduce operational expenditures, including a workforce reduction of over 50% and facility consolidations.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $38,837 | $89,046 | $136,759 | $183,196 |
| Net Loss | $(80,755) | $(56,403) | $(232,012) | $(439,495) |
| Loss Per Share (Diluted) | $(1.45) | $(1.08) | $(4.22) | $(8.58) |
| Operating Cash Flow | — | — | $(123,381) | $(277,150) |
| Cash & Cash Equivalents | $111,065 | $616,214 | $111,065 | $616,214 |
| Marketable Securities | $350,797 | $0 | $350,797 | $0 |
| Total Liquidity | $461,862 | $616,214 | $461,862 | $616,214 |
Note: Q3 2025 Operating Cash Flow is not explicitly provided in the text; only the nine-month figure is available.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 56% in Q3 2025 ($38.8M) compared to Q3 2024 ($89.0M). This was primarily driven by a $45.4M non-cash revenue recognition in Q3 2024 from the termination of the Motif contract, which did not recur in 2025. Cell Engineering revenue dropped from $75.1M to $29.4M, while Biosecurity revenue fell from $14.0M to $9.5M.
- Expense Reduction: Operating expenses decreased significantly due to restructuring. Research and Development (R&D) expenses fell 10% in Q3 and 44% in the nine-month period. General and Administrative (G&A) expenses decreased 14% in Q3 and 27% in the nine-month period.
- Improved Loss Profile: Net loss for the nine months ended September 30, 2025, was $232.0M, a 47% improvement compared to the $439.5M loss in the same period in 2024. This improvement is largely attributable to the absence of a $47.9M goodwill impairment charge recorded in 2024 and reduced operating costs.
- Investment Activity: The company began investing excess cash in marketable debt securities in 2025, holding $350.8M as of September 30, 2025, compared to none in the prior year. Net cash used in investing activities increased to $335.4M (9M 2025) primarily due to these purchases.
Guidance, Outlook, and Risks
- Restructuring Progress: The company expects workforce reductions to be substantially completed in 2025. Facility consolidation is ongoing, with subleasing of excess space expected to extend into 2026. Total restructuring costs for employee termination are estimated between $28.0M and $30.0M.
- Liquidity Outlook: Management believes current cash and marketable securities ($461.9M) are sufficient to fund operations for at least the next 12 months. The company initiated an At-The-Market (ATM) offering program in September 2025, raising $9.4M net proceeds to date.
- Commercial Strategy: The company is shifting focus toward "Cell Engineering Tools" (Datapoints and automation) and reducing reliance on downstream value share (equity/milestones) in new contracts. Non-cash revenue recognition has decreased significantly as legacy contracts with equity consideration mature or terminate.
- Key Risks:
- Contractual Commitments: A $21.4M shortfall liability was recorded regarding a Google Cloud partnership, with a revised agreement requiring a $14.0M one-time payment in Q4 2025 to release minimum commitment obligations.
- Customer Concentration: Revenue remains heavily dependent on U.S. customers (76% of total revenue in 9M 2025) and specific government programs.
- Investment Volatility: The company holds significant equity interests in private companies (e.g., Motif, Genomatica) and notes receivable, which are subject to impairment risks and valuation adjustments.
Investor Verification Checklist
- Google Cloud Liability: Verify the timing and impact of the $14.0M one-time payment required in Q4 2025 to settle the cloud partnership shortfall.
- Restructuring Completion: Monitor the actual completion of workforce reductions and the timeline for subleasing excess facilities, as delays could impact future cost savings.
- Non-Cash Revenue: Confirm the trajectory of non-cash revenue recognition, which dropped from $60.1M (9M 2024) to $9.9M (9M 2025), to assess the quality of future cash flows.
- ATM Offering Utilization: Track the utilization of the $100M ATM program to gauge management's confidence in capital raising versus cash burn.
- Investment Valuations: Review the fair value adjustments of notes receivable and private equity investments, which contributed to a $2.7M downward adjustment in Q3 2025.